Compare Enveric Biosciences Inc (ENVB) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs National Beverage Corp. — how do they compare? Enveric Biosciences Inc trades at $1.56 (market cap $6.20M), while National Beverage Corp. trades at $30.54 (market cap $2.89B). The key difference: National Beverage Corp. is far larger — about 466.1× Enveric Biosciences Inc's market cap. Which is the better fit depends on your goals.
| ENVB | FIZZ | |
|---|---|---|
Market Cap | $6.20M | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $46.75 |
52-Week Low | $1.27 | $30.53 |
Enterprise Value | $1.30M | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.56, up 1.3% on the day, with a bullish technical signal from moving averages and strong analyst support (75% buy ratings). The company reported four consecutive quarterly earnings beats in 2025, including a positive EPS of $0.85 in Q4, while recent news highlights progress in preclinical studies for its non-hallucinogenic psychiatric drug candidate EB-003.
Despite operational losses and negative ROE/ROA, ENVB's consistent earnings surprises and advancing pipeline present speculative growth potential. Key risks include cash burn, clinical trial outcomes, and regulatory hurdles, requiring careful risk assessment by investors.
FIZZ trades at $30.45, down 1.9% on the day, with a bearish technical signal and recent earnings misses. Revenue has stagnated around $1.2B annually, though net income margin improved to 15.56% in 2025. The company announced a special dividend of $3.25 per share, payable in July 2026, but faces declining LaCroix volumes and muted growth prospects.
The outlook is cautious due to stalled growth and bearish analyst sentiment, with 50% of coverage rating Sell. Risks include competitive pressures and weak volume trends, though the dividend provides some shareholder return. Upside appears limited without a clear catalyst for revenue acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
